defer study: 5-year follow-up
DESCRIPTION
DEFER STUDY: 5-YEAR FOLLOW-UP. A Multicenter Randomized Study to Compare Deferral Versus Performance of PCI of Non-Ischemia-Producing Stenoses. Principal investigators. Nico H.J. Pijls, MD, PhD Catharina Hospital Eindhoven, The Netherlands. - PowerPoint PPT PresentationTRANSCRIPT
![Page 1: DEFER STUDY: 5-YEAR FOLLOW-UP](https://reader035.vdocuments.us/reader035/viewer/2022081504/56812b1e550346895d8f1604/html5/thumbnails/1.jpg)
DEFER STUDY: 5-YEAR FOLLOW-UP
Nico H.J. Pijls, MD, PhD Catharina Hospital Eindhoven, The Netherlands
Bernard De Bruyne, MD, PhDCardiovascular Center AalstAalst, Belgium
Principal investigators
A Multicenter Randomized Study A Multicenter Randomized Study to Compare Deferral Versus Performance of PCI to Compare Deferral Versus Performance of PCI of Non-Ischemia-Producing Stenosesof Non-Ischemia-Producing Stenoses
![Page 2: DEFER STUDY: 5-YEAR FOLLOW-UP](https://reader035.vdocuments.us/reader035/viewer/2022081504/56812b1e550346895d8f1604/html5/thumbnails/2.jpg)
Any treatment in health care should be directedeither to
• Releave symptoms ( improve functional class )
or to
• Improve outcome ( prognosis, longevity)
No other justification for any treatment is possible !
NOTE
![Page 3: DEFER STUDY: 5-YEAR FOLLOW-UP](https://reader035.vdocuments.us/reader035/viewer/2022081504/56812b1e550346895d8f1604/html5/thumbnails/3.jpg)
In patients with coronary artery disease,the most important factor with respect to both
• functional class (symptoms)
• and prognosis (outcome)
Is the presence and extent of inducible ischemia
(many invasive & non-invasive studies in > 100,000 patients)
If a stenosis is responsible for reversible ischemia, revascularization improves symptoms(if present) and outcome…..
DEFER study: background (1)
![Page 4: DEFER STUDY: 5-YEAR FOLLOW-UP](https://reader035.vdocuments.us/reader035/viewer/2022081504/56812b1e550346895d8f1604/html5/thumbnails/4.jpg)
DEFER study: background (2)
If a stenosis is responsible for reversible ischemia, revascularization is justified……
……But what if a stenosis or “plaque” is NOT responsible for reversible ischemia ? (functionally “non-significant” , “non-culprit”)
PCI is often performed in such lesions,yet the benefit of such treatment is not clear
![Page 5: DEFER STUDY: 5-YEAR FOLLOW-UP](https://reader035.vdocuments.us/reader035/viewer/2022081504/56812b1e550346895d8f1604/html5/thumbnails/5.jpg)
158 vb38/interm.RCA/Buddem (1)
• female, 58-y-old• underwent PCI of severe LCX lesion a minute before • 50 % stenosis in mid RCA
Should this lesion be stented ??
![Page 6: DEFER STUDY: 5-YEAR FOLLOW-UP](https://reader035.vdocuments.us/reader035/viewer/2022081504/56812b1e550346895d8f1604/html5/thumbnails/6.jpg)
• Fractional Flow Reserve, Fractional Flow Reserve, calculated fromcalculated from coronary pressure measurement, coronary pressure measurement, is an accurate, is an accurate, invasive, and lesion-specific invasive, and lesion-specific indexindex to demonstrate to demonstrate or exclude whether a particular coronary stenosisor exclude whether a particular coronary stenosis can cause can cause reversible ischemiareversible ischemia..
• FFRFFR can be determined easily, in the cath-lab, can be determined easily, in the cath-lab, immediately prior to a planned interventionimmediately prior to a planned intervention
DEFER study: background (3)
FFR based strategy for PCI in equivocal stenosis( DEFER – Study)
![Page 7: DEFER STUDY: 5-YEAR FOLLOW-UP](https://reader035.vdocuments.us/reader035/viewer/2022081504/56812b1e550346895d8f1604/html5/thumbnails/7.jpg)
The DEFER Study: DesignThe DEFER Study: Design
prospective randomized multicentric trial prospective randomized multicentric trial (14 centers) in 325 patients with stable (14 centers) in 325 patients with stable chest pain and an intermediate stenosis chest pain and an intermediate stenosis without objective evidence of ischemiawithout objective evidence of ischemia
AalstAmsterdamEindhoven Essen Gothenborg Hamburg Liège
Maastricht Madrid Osaka Rotterdam Seoul Utrecht Zwolle
data collection & analysis: Jan Willem Bech, MD, PhDPepijn van Schaardenburgh, MD
![Page 8: DEFER STUDY: 5-YEAR FOLLOW-UP](https://reader035.vdocuments.us/reader035/viewer/2022081504/56812b1e550346895d8f1604/html5/thumbnails/8.jpg)
The DEFER Study: The DEFER Study: ObjectivesObjectives
• to test to test safetysafety of deferring PCI of stenoses of deferring PCI of stenoses not responsible for inducible ischemia as not responsible for inducible ischemia as indicated by FFR > 0.75 ( indicated by FFR > 0.75 ( ““outcomeoutcome”” ))
Secondary objectiveSecondary objective
• to compare to compare quality of lifequality of life in such patients, in such patients, whether or not treated by PCI whether or not treated by PCI (CCS-class, need for anti-anginal drugs)(CCS-class, need for anti-anginal drugs) (“symptoms”)(“symptoms”)
Primary objective
![Page 9: DEFER STUDY: 5-YEAR FOLLOW-UP](https://reader035.vdocuments.us/reader035/viewer/2022081504/56812b1e550346895d8f1604/html5/thumbnails/9.jpg)
DEFER Group
REFERENCE Group PERFORM Group
The DEFER Study: Flow ChartPatients scheduled for PCI without Proof of Ischemia
(n=325)
performance of PTCA (158)
deferral of PTCA (167)
FFR 0.75 (91)
No PTCA
FFR 0.75(90)
PTCA
FFR < 0.75(76)
PTCA
FFR < 0.75(68)
PTCA
RandomizationRandomization
![Page 10: DEFER STUDY: 5-YEAR FOLLOW-UP](https://reader035.vdocuments.us/reader035/viewer/2022081504/56812b1e550346895d8f1604/html5/thumbnails/10.jpg)
THE DEFER STUDY: RANDOMIZATION
1 : 1 randomization
deferral of PCI
performance of PCI
If FFR < 0.75 performance anyway reference group
If FFR > 0.75 randomization followed
defer PCI perform PCI
![Page 11: DEFER STUDY: 5-YEAR FOLLOW-UP](https://reader035.vdocuments.us/reader035/viewer/2022081504/56812b1e550346895d8f1604/html5/thumbnails/11.jpg)
The DEFER Study: The DEFER Study: CatheterizationCatheterization
• 6 or 7 F guiding catheter for measurement of aortic pressure ( Pa)
• QCA from 2 orthogonal views
• Coronary pressure measurement (Pd ) by 0.014” pressure wire (Radi Medical Systems)
• Maximum hyperemia by i.v. adenosine (140 ug/kg/min)
• Calculation of Fractional Flow Reserve by:
FFR = Pd / Pa
![Page 12: DEFER STUDY: 5-YEAR FOLLOW-UP](https://reader035.vdocuments.us/reader035/viewer/2022081504/56812b1e550346895d8f1604/html5/thumbnails/12.jpg)
The DEFER Study: Base line data
Randomized to Randomized to Deferral of PTCA Performance of
PTCA N=167 N=158
Diabetes (%) 13 12Hypertension (%) 41 35Hyperlipidemia (%) 47 48Current Smoker (%) 30 25Family History CAD (%) 50 49
Age, (yr) 629 6310Female sex (%) 29 29Ejection Fraction (%) 6710 689
![Page 13: DEFER STUDY: 5-YEAR FOLLOW-UP](https://reader035.vdocuments.us/reader035/viewer/2022081504/56812b1e550346895d8f1604/html5/thumbnails/13.jpg)
The DEFER Study: Baseline QCA and FFR
Ref. diam. (mm) 2.960.63 2.980.57
MLD (mm) 1.420.40
DS (%) 5210
1.420.38 5211
Randomized to Randomized to Deferral of PTCA Performance of PTCA
N=167 N=158
FFR 0.720.19 0.730.19
All baseline characteristics were identical between both groups
![Page 14: DEFER STUDY: 5-YEAR FOLLOW-UP](https://reader035.vdocuments.us/reader035/viewer/2022081504/56812b1e550346895d8f1604/html5/thumbnails/14.jpg)
The DEFER Study: Diameter Stenosis versus FFR
20
30
40
50
60
70
80
90
FFR < 0.75FFR 0.75
DS
%
![Page 15: DEFER STUDY: 5-YEAR FOLLOW-UP](https://reader035.vdocuments.us/reader035/viewer/2022081504/56812b1e550346895d8f1604/html5/thumbnails/15.jpg)
No. at risk
Defer group 90 85 82 74 73 72
Perform group 88 78 73 70 67 65
Reference gr 135 105 103 96 90 88
78.8
72.7
64.4
0 1 2 3 4 50
25
50
75
100
Defer
Perform
Reference(FFR < 0.75)
p=0.52
p=0.17p=0.03
Years of Follow-up
event – free survival (%)
![Page 16: DEFER STUDY: 5-YEAR FOLLOW-UP](https://reader035.vdocuments.us/reader035/viewer/2022081504/56812b1e550346895d8f1604/html5/thumbnails/16.jpg)
72 %72 % 58 %58 %68 %68 %Pts free of angina(%)Pts free of angina(%)
52 (39 %)52 (39 %)24 (27 %)24 (27 %)19 (21 %)19 (21 %)Patients Patients ≥1 event (%)≥1 event (%)
707029292121Total eventsTotal events
2 (1.5)2 (1.5)1 (1.1)1 (1.1)00Other (%)Other (%)
11 (8.2)11 (8.2)6 (6.8)6 (6.8)6 (6.7)6 (6.7)Non-TLR(%)Non-TLR(%)
14 (10.4)14 (10.4)4 (4.5)4 (4.5)1 (1.1) 1 (1.1) CABG(%)CABG(%)
7 (5.2)7 (5.2)1 (1.1)1 (1.1)00Non-Q wave MI(%)Non-Q wave MI(%)
6 (4.5)6 (4.5)4 (4.5)4 (4.5)00Q wave MI (%)Q wave MI (%)
4 (3.0)4 (3.0)3 (3.4)3 (3.4)3 (3.3)3 (3.3)Non Cardiac Death(%)Non Cardiac Death(%)
8 (6.0)8 (6.0)2 (2.3)2 (2.3)3 (3.3)3 (3.3)Cardiac Death(%)Cardiac Death(%)
14414490909191Number of patientsNumber of patients
ReferenceReferencePerformPerformDeferDefer
FFR<0.75FFR<0.75FFR FFR ≥0.75≥0.75
18 (13.4)18 (13.4)8 (9.1)8 (9.1)8 (8.9)8 (8.9)TLR(%)TLR(%)
DEFER: Clinical Outcome at 5 YearsDEFER: Clinical Outcome at 5 Years
Lost to follow-up 1 2 10Lost to follow-up 1 2 10
![Page 17: DEFER STUDY: 5-YEAR FOLLOW-UP](https://reader035.vdocuments.us/reader035/viewer/2022081504/56812b1e550346895d8f1604/html5/thumbnails/17.jpg)
Cardiac Death And Acute MI After 5 Years
3.3
7.9
15.7
0
5
10
15
20 %
P=0.20
P< 0.03
P< 0.005
DEFER PERFORM REFERENCE
FFR > 0.75 FFR < 0.75
![Page 18: DEFER STUDY: 5-YEAR FOLLOW-UP](https://reader035.vdocuments.us/reader035/viewer/2022081504/56812b1e550346895d8f1604/html5/thumbnails/18.jpg)
0%
20%
40%
60%
80%
100%
baseline 1month 1 year 2 year 5 year
Defer group Perform group Reference group
freedom from chest pain
FFR > 0.75 FFR > 0.75 FFR < 0.75
* *
* *
* **
*
![Page 19: DEFER STUDY: 5-YEAR FOLLOW-UP](https://reader035.vdocuments.us/reader035/viewer/2022081504/56812b1e550346895d8f1604/html5/thumbnails/19.jpg)
DEFER: Summary and Conclusions (1)DEFER: Summary and Conclusions (1)
1.1. In patients with stable chest pain, the most important In patients with stable chest pain, the most important prognostic factor of a given coronary artery stenosis, prognostic factor of a given coronary artery stenosis, is its ability of inducing myocardial ischemia (as is its ability of inducing myocardial ischemia (as reflected by FFR < 0.75)reflected by FFR < 0.75)
2.2. In those patients, clinical outcome of such “ischemic” In those patients, clinical outcome of such “ischemic” stenosis, even when treated by PCI, is much worse stenosis, even when treated by PCI, is much worse than that of a functionally “non-significant” stenosis.than that of a functionally “non-significant” stenosis.
3. The prognosis of “non-ischemic” stenosis (FFR > 0.75) 3. The prognosis of “non-ischemic” stenosis (FFR > 0.75) is excellent and the risk of such “non-significant” is excellent and the risk of such “non-significant” stenosis or plaque to cause death or AMI is < 1% per stenosis or plaque to cause death or AMI is < 1% per year, year, and not decreased by stentingand not decreased by stenting
![Page 20: DEFER STUDY: 5-YEAR FOLLOW-UP](https://reader035.vdocuments.us/reader035/viewer/2022081504/56812b1e550346895d8f1604/html5/thumbnails/20.jpg)
DEFER: Summary and Conclusions (2)DEFER: Summary and Conclusions (2)
Conclusion
Stenting a “non-ischemic” stenosis does not Stenting a “non-ischemic” stenosis does not benefit patients with stable chest pain, neither benefit patients with stable chest pain, neither
in prognostic nor symptomatic respect.in prognostic nor symptomatic respect.
![Page 21: DEFER STUDY: 5-YEAR FOLLOW-UP](https://reader035.vdocuments.us/reader035/viewer/2022081504/56812b1e550346895d8f1604/html5/thumbnails/21.jpg)
No. at risk
FFR ≥ 0.75 178 162 154 143 138 136
FFR < 0.75 135 105 103 96 90 88
75.8
64.4
0 1 2 3 4 50
25
50
75
100
FFR 0.75
FFR < 0.75p=0.03
Years of Follow-up
event – free survival (%)